Respiratory Syncytial Virus (RSV) Clinical Trials

171 clinical trials for Respiratory Syncytial Virus (RSV) across international registries, including 38 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF — RECRUITING · PHASE3
• A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus — RECRUITING · PHASE2
• Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease — RECRUITING · NA
• A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. — RECRUITING · PHASE3
• Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age — RECRUITING · PHASE1
• Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective — RECRUITING
• Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons — RECRUITING · PHASE2
• Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell) — RECRUITING · PHASE3
• A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea — RECRUITING
• A Clinical Trial of SIBP-A16 Injection in Healthy Adults — RECRUITING · PHASE1
• Antibiotic Therapy in Viral Airway Infections — RECRUITING · PHASE4
• Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV — RECRUITING · PHASE2
• Assessing Antiviral Treatments in Early Symptomatic RSV — RECRUITING · PHASE2
• Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia — RECRUITING · NA
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine — RECRUITING · PHASE1
• RSV Vaccine Pregnancy Registry — RECRUITING
• A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL (RSV) PERFUSION F SUBUNIT VACCINE IN ADULTS — RECRUITING · PHASE3
• A PHASE 3B, OPEN-LABEL STUDY TO EVALUATE THE NON-INFERIORITY OF THE IMMUNE RESPONSE AND TO EVALUATE THE SAFETY OF THE RSVPREF3 OA INVESTIGATIONAL VACCINE IN ADULTS 18-49 YEARS OF AGE AT INCREASED RISK FOR RESPIRATORY SYNCYTIAL VIRUS DISEASE, COMPARED TO OLDER ADULTS ¿60 YEARS OF AGE — RECRUITING · PHASE3
• AN INTERVENTIONAL PHASE 2/3, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS — RECRUITING · PHASE2
• A PHASE 3 STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF MRNA-1345, AN MRNA VACCINE TARGETING RESPIRATORY SYNCYTIAL VIRUS, IN HIGH-RISK ADULTS — RECRUITING · PHASE3
• A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY TO EVALUATE THE IMMUNE RESPONSE, SAFETY AND REACTOGENICITY OF RSVPREF3 OA INVESTIGATIONAL VACCINE WHEN CO-ADMINISTERED WITH HERPES ZOSTER RECOMBINANT SUBUNIT (HZ/SU) VACCINE IN ADULTS AGED 50 YEARS AND OLDER — RECRUITING · PHASE3
• A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE NONINFERIORITY OF THE IMMUNE RESPONSE AND SAFETY OF THE RSVPREF3 OA INVESTIGATIONAL VACCINE IN ADULTS 50-59 YEARS OF AGE, INCLUDING ADULTS AT INCREASED RISK OF RESPIRATORY SYNCYTIAL VIRUS LOWER RESPIRATORY TRACT DISEASE, COMPARED TO OLDER ADULTS ¿60 YEARS OF AGE — RECRUITING · PHASE3
• A PHASE 3, MULTICENTER, RANDOMIZED, PARTIALLY BLINDED, PALIVIZUMAB CONTROLLED STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF MK-1654 IN INFANTS AND CHILDREN AT INCREASED RISK FOR SEVERE RSV DISEASE — RECRUITING · PHASE3
• PHASE 2/3, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1345, AN MRNA VACCINE TARGETING RESPIRATORY SYNCYTIAL VIRUS (RSV), IN ADULTS ¿ 60 YEARS OF AGE — RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, DOUBLE BLIND, MULTI COUNTRY STUDY TO EVALUATE CONSISTENCY, SAFETY, AND REACTOGENICITY OF 3 LOTS OF RSVPREF3 OA INVESTIGATIONAL VACCINE ADMINISTRATED AS A SINGLE DOSE IN ADULTS AGED 60 YEARS AND ABOVE — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNTRY STUDY TO DEMONSTRATE THE EFFICACY OF A SINGLE OF GSK¿S RSVPREF3 OA INVESTIGATIONAL VACCINE IN ADULTS AGED 60 YEARS AND ABOVE — RECRUITING · PHASE3
• A PHASE 2B/3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-1654 IN HEALTHY PRE-TERM AND FULL-TERM INFANTS — RECRUITING · PHASE2
• A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTRY STUDY TO DEMONSTRATE EFFICACY OF A SINGLE DOSE OF UNADJUVANTED RSV MATERNAL VACCINE, ADMINISTERED IM TO PREGNANT WOMEN 18 TO 49 YEARS OF AGE, FOR PREVENTION OF RSV ASSOCIATED LRTI IN THEIR INFANTS UP TO 6 MONTHS OF AGE — RECRUITING · PHASE3
• A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EDP-938 ADMINISTERED ORALLY FOR THE TREATMENT OF ACUTE UPPER RESPIRATORY TRACT INFECTION WITH RESPIRATORY SYNCYTIAL VIRUS IN AMBULATORY ADULT SUBJECTS (RSVP) — RECRUITING · PHASE2
• "PHASE II RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, MULTI-COUNTRY STUDY IN HEALTHY NON-PREGNANT WOMEN 18-45 YEARS OF AGE TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF A SINGLE INTRAMUSCULAR DOSE OF GSK BIOLOGICALS¿ INVESTIGATIONAL RSV MATERNAL VACCINE (GSK388550A) WHEN GIVEN ALONE AND GIVEN IN COADMINISTRATION WITH A SINGLE INTRAMUSCULAR DOSE OF BOOSTRIX (US FORMULATION SB776423 OR EX-US FORMULATION SB263855)." — RECRUITING · PHASE2
• A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PALIVAZUMAB-CONTROLLED STUDY TO EVALUATE THE SAFETY OF MEDI8897, A MONOCLONAL ANTIBODY WITH AN EXTENDED HALF-LIFE AGAINST RESPIRATORY SYNCYTIAL VIRUS, IN HIGH-RISK CHILDREN (MEDLEY) — RECRUITING · PHASE2
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MEDI 8897, A MONOCLONAL ANTIBODY WITH AN EXTENDED HALF-LIFE AGAINST RESPIRATORY SYNCYTIAL VIRUS, IN HEALTHY LATE PRETERM AND TERM INFANTS (MELODY) — RECRUITING · PHASE3
• "A PHASE 1/2, RANDOMIZED, OBSERVER-BLIND, CONTROLLED, MULTI-CENTER STUDY TO EVALUATE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF GSK BIOLOGICALS¿ RESPIRATORY SYNCYTIAL VIRUS (RSV) INVESTIGATIONAL VACCINE BASED ON THE RSV VIRAL PROTEINS F, N AND M2-1 ENCODED BY CHIMPANZEE-DERIVED ADENOVECTOR (CHAD155-RSV) (GSK3389245A), WHEN ADMINISTERED INTRAMUSCULARLY AS A SINGLE DOSE OR AS TWO DOSES ACCORDING TO A 0, 1-MONTH SCHEDULE, TO INFANTS AGED 6 AND 7 MONTHS." — RECRUITING · PHASE1
• A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MEDI8897, A MONOCLONAL ANTIBODY WITH AN EXTENDED HALF-LIFE AGAINST RESPIRATORY SYNCYTIAL VIRUS, IN HEALTH PRETERM INFANTS — RECRUITING · PHASE2
• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE ANTIVIRAL ACTIVITY, CLINICAL OUTCOMES, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORALLY ADMINISTERED ALS-008176 REGIMENS IN ADULT SUBJECTS HOSPITALIZED WITH RESPIRATORY SYNCYTIAL VIRUS — RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF A HUMAN MONOCLONAL ANTIBODY, REGN2222, FOR THE PREVENTION OF MEDICALLY ATTENDED RSV INFECTION IN PRETERM INFANTS — RECRUITING · PHASE3
• A PHASE 2B RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF MEDI7510 FOR THE PREVENTION OF ACUTE RESPIRATORY SYNCYTIAL VIRUS-ASSOCIATED RESPIRATORY ILLNESS IN OLDER ADULTS — RECRUITING · PHASE2
• A RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE SAFETY AND REACTOGENICITY OF DPX-RSV(A), A RESPIRATORY SYNCYTIAL VIRUS VACCINE, CONTAINING OF RESPIRATORY SYNCYTIAL VIRUS (RSV)(A) SHE ANTIGEN AND A NOVEL ADJUVANT DEPOVAXTM, IN HEALTH ADULTS — RECRUITING
• Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection — COMPLETED · PHASE2
• A study to rank different dosages of antigen of GlaxoSmithKline (GSK) Biologicals’ investigational Respiratory Syncytial Virus (RSV) vaccine (GSK3003891A), based on their immune response and safety, when administered to healthy adult women. — COMPLETED · PHASE2
• A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults — NOT_YET_RECRUITING · PHASE1
• Systems Biological Analysis of Immune Responses to RSV Vaccine — ACTIVE_NOT_RECRUITING · PHASE4
• A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease — TERMINATED · PHASE2
• A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection — NOT_YET_RECRUITING · PHASE1
• A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants — COMPLETED · PHASE3
• Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos — NOT_YET_RECRUITING
• Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)-RSV immunisation adaptive platform trial — TERMINATED · PHASE3
• A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months — ACTIVE_NOT_RECRUITING · PHASE1
• Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants — ACTIVE_NOT_RECRUITING
• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers — COMPLETED · PHASE2

Refine this search